Business
Time to debunk anti-vaxxer myths: CSL CEO – The Australian Financial Review
Demand for CSL’s core plasma products and surging government orders for flu vaccines has resulted in the biotech giant lifting the bottom end of its 2021 profit…
“We don’t have the ability to just turn on a dime and start making more flu vaccines … when we start the manufacturing process it’s pretty well done… and to turn and make more is very difficult late in the season, but we’ve had good yield
-
Noosa News23 hours agoBrisbane vs Collingwood live blog: Richmond selects Noah Balta as unbeaten Lions prepare for Magpies test
-
General24 hours agoCanberra man named as doctor accused of rape after suppression order lifted
-
General22 hours agoNT Coalition candidate Lisa Siebert diverges from Jacinta Nampijinpa Price on royal commission call
-
Noosa News23 hours agoMelbourne Market vendors say new rent offer too expensive as eviction threat looms